<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:chebi fb="11" ids="26333">Prostaglandin</z:chebi> (PG) E2 is known to be closely related to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> and is inactivated by 15-hydroxyprostaglandin dehydrogenase (PGDH) </plain></SENT>
<SENT sid="1" pm="."><plain>15-PGDH is shown to have <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor activity and to be down-regulated in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we evaluated the expression of 15-PGDH and its prognostic effect in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: 15-PGDH expression was examined by using immunohistochemistry in 77 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Its prognostic significance was statistically evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Negative 15-PGDH expression was noted in 55.8% of the 77 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>15-PGDH expression showed no correlation with any of the various clinicopathologic parameters </plain></SENT>
<SENT sid="7" pm="."><plain>The status of lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-node-<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> stages, and pre-operative carcinoembryonic antigen levels showed significant prognostic effect </plain></SENT>
<SENT sid="8" pm="."><plain>However, univariate analysis revealed down-regulation of 15-PGDH not to be a predictor of poor survival </plain></SENT>
<SENT sid="9" pm="."><plain>The 5-year overall survival rate was 71.7% in the group with positive expression of 15-PGDH and 67.1% in the group with negative expression of 15-PGDH, but this difference was not statistically significant (P = 0.751) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: 15-PGDH was down-regulated in 55.8% of the <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="11" pm="."><plain>However, down-regulation of 15-PGDH showed no prognostic value in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Further larger scale or prospective studies are needed to clarify the prognostic effect of 15-PGDH down-regulation in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>